Breakthrough Findings with CQ-001

• In-Vivo Efficacy: Completed rodent trials at Western University and MES mouse models at Ontario Brain Institute.
• Superior Potency: 35% greater seizure protection isolated CBD in preclinical epilepsy models.
• Enhanced Safety: Lower dosages with fewer adverse effects compared to existing treatments.

Therapeutic Impact Beyond Epilepsy

• Positive outcomes on anxiety, depression, PTSD, memory consolidation, and cognitive health.

Strategic Advantages

• De-risked pathway leveraging Epidiolex® safety data for bioequivalence (BE) study → Phase IIb/III trial → NDA submission.
• Positioned for Orphan Drug Status with 7-year exclusivity potential.

 

“After examining CanaQuest's portfolio, I recognize the opportunity for CQ-001 to build on the successes of previously approved cannabidiol-based medications. With its combination of active compounds, preliminary data suggests that CQ-001 may offer enhanced benefits by targeting multiple mechanisms of action beyond those of cannabidiol alone.”

Dr. Jordyn Stuart, PhD

CanaQuest Acting Chief Scientific Officer

 

 

PTSD: post-traumatic stress disorder; TBI: traumatic brain injury, IP: intellectual property; CNS: central nervous system